Sulbutiamine for Health & Longevity - Quick Reference Sheet

Sulbutiamine for Health & Longevity

Created on 08/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A fat-soluble form of vitamin B1 that reaches the brain more easily than the ordinary vitamin. Its most credible benefit is a modest, short-term easing of fatigue, especially fatigue tied to a known cause. Effects on memory, mood, and nerve symptoms stay unproven. Generally well tolerated short-term; the main worry is mood elevation in susceptible people. (Full Review)

Protocol

Dose
400–600 mg/day
200 mg tablets; nootropic users often start ~200 mg
Frequency
2–3 split doses
e.g., 200 mg twice daily; ~5-hour half-life
Timing
Morning / early afternoon
late-day dosing risks insomnia
Time to effect
Fatigue / asthenia
1–4 weeks
window over which asthenia studies assessed benefit
Energy & focus
Within hours
some users report acute effects per dose
Trial period
A few weeks
realistic period to judge response

Benefits

Contraindications
  • Bipolar disorder or other psychotic-spectrum conditions
  • History of substance-use disorder
  • Pregnancy or breastfeeding
  • Competitive athletes and military
Key Interactions
  • Mood stabilizers and psychiatric medications (lithium, valproate, antipsychotics)
  • Stimulants and activating agents (amphetamines, methylphenidate, high-dose caffeine)
  • Acetylcholinesterase inhibitors (e.g., donepezil)
  • Antidepressants and pro-dopaminergic agents (e.g., bupropion)
  • Alcohol
  • Other stimulant/energy nootropics (caffeine, benfotiamine, high-dose L-Tyrosine)

Risk & Side Effects

  • High:
  • Medium: Mild gastrointestinal upset, headache, and insomnia
  • Low: Dermatologic hypersensitivity reactions; psychiatric activation and mood destabilization; tolerance, psychological dependence, and misuse
  • Speculative: Unknown long-term and high-dose safety

Monitoring

Marker Target Why
Whole-blood thiamine / erythrocyte transketolase Within or above mid reference range Confirms whether a true thiamine deficiency underlies fatigue
HbA1c < 5.4% (functional) Contextual marker in the diabetic-neuropathy setting

Cadence: Reassess symptoms and mood at 1–2 weeks and at 4 weeks; if used intermittently long-term, review at each cycle or roughly every 3–6 months.

Qualitative Assessment

  • Energy and fatigue levels
  • Cognitive clarity, focus, and motivation
  • Mood and drive — improvement without agitation, anxiety, or sleep disruption
  • Sleep quality (safety marker)
  • Absence of dose escalation over time